HRP20021039B1 - Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja - Google Patents

Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Info

Publication number: HRP20021039B1
Authority: HR; Croatia
Prior art keywords: optionally substituted; halogen; independently selected; ora; heteroaryl
Prior art date: 2000-07-25

Application number

HR20021039A

Other languages

English (en)

Croatian (hr)

Inventor

Labelle Marc

Sturino Claudio

Roy Bruno

Berthelette Carl

Boyd Michael

Lachance Nicolas

Scheigetz John

Original Assignee

Merck Frosst Canada & Co.

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-07-25

Filing date

2001-07-23

Publication date

2011-03-31

2001-07-23 Application filed by Merck Frosst Canada & Co. filed Critical Merck Frosst Canada & Co.

2004-10-31 Publication of HRP20021039A2 publication Critical patent/HRP20021039A2/hr

2011-03-31 Publication of HRP20021039B1 publication Critical patent/HRP20021039B1/xx

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/38—TPC being performed in particular situations
- H04W52/46—TPC being performed in particular situations in multi-hop networks, e.g. wireless relay networks
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/94—[b, c]- or [b, d]-condensed containing carbocyclic rings other than six-membered
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04B—TRANSMISSION
- H04B17/00—Monitoring; Testing
- H04B17/30—Monitoring; Testing of propagation channels
- H04B17/309—Measuring or estimating channel quality parameters
- H04B17/318—Received signal strength
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/02—Access restriction performed under specific conditions
- H04W48/04—Access restriction performed under specific conditions based on user or terminal location or mobility data, e.g. moving direction, speed
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/06—TPC algorithms
- H04W52/14—Separate analysis of uplink or downlink
- H04W52/146—Uplink power control
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/28—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission
- H04W52/288—TPC being performed according to specific parameters using user profile, e.g. mobile speed, priority or network state, e.g. standby, idle or non-transmission taking into account the usage mode, e.g. hands-free, data transmission or telephone
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W48/00—Access restriction; Network selection; Access point selection
- H04W48/20—Selecting an access point
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/245—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters taking into account received signal strength
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04W—WIRELESS COMMUNICATION NETWORKS
- H04W52/00—Power management, e.g. Transmission Power Control [TPC] or power classes
- H04W52/04—Transmission power control [TPC]
- H04W52/18—TPC being performed according to specific parameters
- H04W52/24—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters
- H04W52/247—TPC being performed according to specific parameters using SIR [Signal to Interference Ratio] or other wireless path parameters where the output power of a terminal is based on a path parameter sent by another terminal

Landscapes

Engineering & Computer Science (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Signal Processing (AREA)
Computer Networks & Wireless Communication (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pulmonology (AREA)
Computer Security & Cryptography (AREA)
Otolaryngology (AREA)
Quality & Reliability (AREA)
Physics & Mathematics (AREA)
Electromagnetism (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Agricultural Chemicals And Associated Chemicals (AREA)
Steroid Compounds (AREA)
Plural Heterocyclic Compounds (AREA)
Indole Compounds (AREA)
Materials For Photolithography (AREA)

HR20021039A 2000-07-25 2001-07-23 Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja HRP20021039B1 (hr)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US22068300P	2000-07-25	2000-07-25
PCT/CA2001/001069 WO2002008186A2 (en)	2000-07-25	2001-07-23	Cyclopentanoindoles, compositions containing such compounds and methods of treatment

Publications (2)

Publication Number	Publication Date
HRP20021039A2 HRP20021039A2 (en)	2004-10-31
HRP20021039B1 true HRP20021039B1 (hr)	2011-03-31

Family

ID=22824535

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
HR20021039A HRP20021039B1 (hr)	2000-07-25	2001-07-23	Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja

Country Status (33)

Country	Link
US (1)	US6410583B1 (es)
EP (1)	EP1305286B1 (es)
JP (1)	JP4119745B2 (es)
KR (1)	KR100746814B1 (es)
CN (1)	CN1214007C (es)
AT (1)	ATE284388T1 (es)
AU (2)	AU2001277430B2 (es)
BG (1)	BG66084B1 (es)
BR (1)	BR0112756A (es)
CA (1)	CA2416867C (es)
CZ (1)	CZ2003236A3 (es)
DE (1)	DE60107687T2 (es)
DK (1)	DK1305286T3 (es)
DZ (1)	DZ3402A1 (es)
EA (1)	EA006765B1 (es)
EC (1)	ECSP034428A (es)
EE (1)	EE05287B1 (es)
ES (1)	ES2231526T3 (es)
GE (1)	GEP20053595B (es)
HR (1)	HRP20021039B1 (es)
HU (1)	HUP0301745A3 (es)
IL (2)	IL153406A0 (es)
IS (1)	IS2170B (es)
MX (1)	MXPA03000710A (es)
NO (1)	NO325011B1 (es)
NZ (1)	NZ523106A (es)
PL (1)	PL207342B1 (es)
PT (1)	PT1305286E (es)
RS (1)	RS50491B (es)
SK (1)	SK287507B6 (es)
UA (1)	UA73787C2 (es)
WO (1)	WO2002008186A2 (es)
ZA (1)	ZA200300554B (es)

Families Citing this family (53)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6979456B1 (en)	1998-04-01	2005-12-27	Jagotec Ag	Anticancer compositions
HK1040195B (zh)	1998-08-19	2006-06-02	Skyepharma Canada Inc.	普鲁泊福的可注射水分散体
US7273883B2 (en) *	2000-09-14	2007-09-25	Allergan, Inc.	Prostaglandin EP4 antagonist
US7217725B2 (en) *	2000-09-14	2007-05-15	Allergan, Inc.	Prostaglandin D2 antagonist
US6784172B2 (en)	2000-11-03	2004-08-31	Wyeth	Processes for preparation of cyclopenta[b][1,4]diazepino[6,7,1-hi]indoles and derivatives
AR031195A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Procedimiento para la preparacion de derivados de 1,2,3,4,8,9,10,10a-octahidro-7bh-ciclopenta (b) (1,4) diazepino (6,7,1) diazepino (6,7,1-hi) indol
DE60106641T2 (de) *	2000-11-03	2005-12-01	Wyeth	Cyclopenta[b][1,4] diazepino[6,7,1-hi]indole als 5ht2c antagonisten
AR031200A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Cicloocta [b] [1,4] diazepino [6,7,1-hi] indoles y derivados
AR031202A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Ciclopenta(b) (1,4)diazepino(6,7,1-hi) indoles y derivados
US7141563B2 (en)	2000-11-03	2006-11-28	Wyeth	Process for the preparation of 1, 2, 3, 4, 8, 9, 10, 10a-octahydro-7bH-cyclopenta[b] [1, 4]diazepino[6, 7, 1-hi] indole derivatives
AR031199A1 (es)	2000-11-03	2003-09-10	Wyeth Corp	Ciclohepta/b//1,4/diacepino/6,7,1-hi/indoles y derivados
AR038136A1 (es) *	2002-01-24	2004-12-29	Merck Frosst Canada Inc	Cicloalcanindoles con sustitucion con fluor composiciones que contienen estos compuestos y metodos de tratamiento
TWI312781B (en)	2002-04-25	2009-08-01		[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200307540A (en)	2002-04-25	2003-12-16	Wyeth Corp	[1, 4]Diazocino[7, 8, 1-hi] indole derivatives as antipsychotic and antiobesity agents
TW200307682A (en)	2002-04-25	2003-12-16	Wyeth Corp	1,2,3,4,7,8-Hexahydro-6H-[1,4]diazepino[6,7,1-ij]quinoline derivatives as antipsychotic and antiobesity agents
TW200400818A (en)	2002-05-21	2004-01-16	Wyeth Corp	Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus
TW200400963A (en)	2002-05-21	2004-01-16	Wyeth Corp	R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease
AR041089A1 (es) *	2003-05-15	2005-05-04	Merck & Co Inc	Procedimiento y composiciones farmaceutiicas para tratar aterosclerosis, dislipidemias y afecciones relacionadas
WO2004103970A1 (en) *	2003-05-20	2004-12-02	Merck Frosst Canada Ltd.	Fluoro-methanesulfonyl-substituted cycloalkanoindoles and their use as prostaglandin d2 antagonists
WO2004111047A2 (en) *	2003-06-12	2004-12-23	Merck Frosst Canada Ltd.	Cycloalkanepyrrolopyridines as dp receptor antagonists
US20080153817A1 (en) *	2003-08-07	2008-06-26	Dirk Beher	Treatment for Alzheimer's Disease and Related Conditions
US20050107350A1 (en) *	2003-08-22	2005-05-19	Pharmacia Corporation	Method for the treatment or prevention of bone disorders with a cyclooxygenase-2 inhibitor alone and in combination with a bone disorder treatment agent and compositions therewith
TWI258478B (en)	2003-10-31	2006-07-21	Arena Pharm Inc	Tetrazole derivatives and methods of treatment of metabolic-related disorders thereof
US7019022B2 (en) *	2003-12-15	2006-03-28	Merck Frosst Canada & Co.	Substituted tetrahydrocarbazole and cyclopentanoindole derivatives
US8039464B2 (en)	2004-07-16	2011-10-18	Proteosys Ag	Muscarinic antagonists with PARP and SIR modulating activity as agents for inflammatory diseases
GT200500284A (es) *	2004-10-15	2006-03-27	Aventis Pharma Inc	Pirimidinas como antagonistas del receptor de prostaglandina d2
GT200500317A (es)	2004-11-05	2006-10-27		Proceso para preparar compuestos de quinolina y productos obtenidos de los mismos
PE20060949A1 (es)	2004-12-23	2006-10-11	Arena Pharm Inc	Derivados fusionados de pirazol como agonistas del receptor de niacina
EP1874301A4 (en) *	2005-04-13	2009-05-06	Merck & Co Inc	Niacin receptor agonists, compositions containing such compounds and treatment methods
US7902177B2 (en) *	2005-05-02	2011-03-08	Wandzel Richard A	Treatment of congestion using steroids and adrenergics
AR054849A1 (es)	2005-07-26	2007-07-18	Wyeth Corp	Diazepinoquinolinas, sintesis de las mismas, e intermediarios para obtenerlas
WO2008097535A2 (en) *	2007-02-08	2008-08-14	Merck & Co., Inc.	Method of treating atherosclerosis, dyslipidemias and related conditions
KR20220084423A (ko)	2008-07-23	2022-06-21	아레나 파마슈티칼스, 인크.	자가면역성 및 염증성의 장애의 치료에 유용한 치환된 1,2,3,4-테트라히드로시클로펜타[ｂ]인돌-3-일)아세트산 유도체
CA2733671C (en) *	2008-08-27	2018-01-02	Arena Pharmaceuticals, Inc.	Substituted tricyclic acid derivatives as s1p1 receptor agonists useful in the treatment of autoimmune and inflammatory disorders
US8507473B2 (en)	2008-09-11	2013-08-13	Arena Pharmaceuticals, Inc.	3H-imidazo[4,5-b]pyridin-5-ol derivatives useful in the treatment of GPR81 receptor disorders
EP2346866B1 (en)	2008-09-25	2013-11-27	Merck Canada Inc.	Beta-carboline sulphonylurea derivatives as ep4 receptor antagonists
WO2010081825A2 (en)	2009-01-13	2010-07-22	Proteosys Ag	Pirenzepine as an agent in cancer treatment
WO2011051151A1 (de)	2009-10-26	2011-05-05	Bayer Cropscience Ag	Neue feste form von 4-[[(6-chlorpyridin-3-yl)methyl](2,2-difluorethyl)amino]furan-2(5h)-on
CA2786994C (en)	2010-01-27	2018-01-16	Arena Pharmaceuticals, Inc.	Processes for the preparation of (r)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof
CN102884064B (zh)	2010-03-03	2016-01-13	艾尼纳制药公司	制备s1p1受体调节剂及其晶体形式的方法
US9797903B2 (en)	2012-10-24	2017-10-24	Winthrop-University Hospital	Non-invasive biomarker to identify subject at risk of preterm delivery
MX386419B (es)	2015-01-06	2025-03-18	Arena Pharm Inc	Metodos de condiciones de tratamiento relacionadas con el receptor s1p1.
JP6770522B2 (ja) *	2015-02-13	2020-10-14	アンスティチュナショナルドゥラサンテエドゥラルシェルシュメディカル	全身性エリテマトーデスを予防し、及び／又は、治療するためのｐｔｇｄｒ−１及び／又はｐｔｇｄｒ−２アンタゴニスト
MA42807A (fr)	2015-06-22	2018-07-25	Arena Pharm Inc	Sel l-arginine cristallin d'acide (r)-2-(7-(4-cyclopentyl-3-(trifluorométhyl)benzyloxy)-1,2,3,4-tétrahydrocyclo-penta[b]indol-3-yl)acétique (composé 1) pour une utilisation dans des troubles associés au récepteur de s1p1
KR20190116416A (ko)	2017-02-16	2019-10-14	아레나 파마슈티칼스, 인크.	원발 담즙성 담관염을 치료하기 위한 화합물 및 방법
MX2019009843A (es)	2017-02-16	2020-01-30	Arena Pharm Inc	Compuestos y metodos para el tratamiento de la enfermedad inflamatoria intestinal con manifestaciones extraintestinales.
MX2020002788A (es)	2017-09-13	2020-09-14	Progenity Inc	Biomarcadores de preeclampsia y sistemas y metodos relacionados.
US11279656B2 (en) *	2017-10-27	2022-03-22	Applied Materials, Inc.	Nanopowders, nanoceramic materials and methods of making and use thereof
KR102859841B1 (ko)	2018-06-06	2025-09-12	아레나 파마슈티칼스, 인크.	S1p1 수용체와 관련된 병태의 치료 방법
CN112955431A (zh)	2018-09-06	2021-06-11	艾尼纳制药公司	可用于治疗自身免疫性病症和炎性病症的化合物
EP4070113A4 (en)	2019-12-04	2023-12-20	Biora Therapeutics, Inc.	ASSESSMENT OF PREECLAMPSIA USING FREE AND DISSOCIATE PLACENTAL GROWTH FACTOR TESTS
CN115260173B (zh) *	2021-04-30	2024-08-30	厦门宝太生物科技股份有限公司	环戊烷并吲哚类支链酸衍生物及其制备方法和应用
CN116854622A (zh) *	2023-07-10	2023-10-10	青岛科技大学	一种多取代的2,4-二氢环戊二烯并[b]吲哚类化合物的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
EP0234708A1 (en) *	1986-01-23	1987-09-02	Merck Frosst Canada Inc.	Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) *	1990-07-26	1992-01-29	Merck Frosst Canada Inc.	(Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
BE787444A (fr)	1971-08-13	1973-02-12	Hoffmann La Roche	Composes polycycliques
US4009181A (en)	1973-01-22	1977-02-22	Hoffmann-La Roche Inc.	Cyclopenta[b]indole-2-carboxylic acids and derivatives thereof
US4057559A (en)	1973-10-01	1977-11-08	American Home Products Corporation	Carbazole acetic acid derivatives
US4808608A (en)	1986-01-23	1989-02-28	Merck & Co., Inc.	Tetrahydrocarbazole 1-alkanoic acids, pharmaceutical compositions and use
GB9101375D0 (en)	1991-01-22	1991-03-06	Erba Carlo Spa	N-imidazolyl derivatives of substituted tetrahydrocarbazole and cyclohepht(b)indole
HUP9802678A3 (en) *	1995-06-21	1999-12-28	Shionogi & Co	Bicyclic amino derivatives and pgd2 antagonist containing the same
JP3215441B2 (ja) *	1996-12-13	2001-10-09	塩野義製薬株式会社	ベンゾチオフェンカルボン酸アミド誘導体およびそれを含有するｐｇｄ２拮抗剤
WO1999062555A1 (en) *	1998-06-03	1999-12-09	Shionogi & Co., Ltd.	Remedies for itching containing pgd2 antagonists

2001
- 2001-07-20 US US09/909,636 patent/US6410583B1/en not_active Expired - Lifetime
- 2001-07-23 NZ NZ523106A patent/NZ523106A/en not_active IP Right Cessation
- 2001-07-23 PT PT01955162T patent/PT1305286E/pt unknown
- 2001-07-23 PL PL363168A patent/PL207342B1/pl not_active IP Right Cessation
- 2001-07-23 DZ DZ013402A patent/DZ3402A1/fr active
- 2001-07-23 RS YUP-979/02A patent/RS50491B/sr unknown
- 2001-07-23 GE GE5105A patent/GEP20053595B/en unknown
- 2001-07-23 EE EEP200300033A patent/EE05287B1/xx not_active IP Right Cessation
- 2001-07-23 MX MXPA03000710A patent/MXPA03000710A/es active IP Right Grant
- 2001-07-23 JP JP2002514093A patent/JP4119745B2/ja not_active Expired - Fee Related
- 2001-07-23 SK SK93-2003A patent/SK287507B6/sk not_active IP Right Cessation
- 2001-07-23 CN CNB018131662A patent/CN1214007C/zh not_active Expired - Fee Related
- 2001-07-23 UA UA2003021565A patent/UA73787C2/uk unknown
- 2001-07-23 CZ CZ2003236A patent/CZ2003236A3/cs unknown
- 2001-07-23 EP EP01955162A patent/EP1305286B1/en not_active Expired - Lifetime
- 2001-07-23 EA EA200300171A patent/EA006765B1/ru not_active IP Right Cessation
- 2001-07-23 CA CA002416867A patent/CA2416867C/en not_active Expired - Fee Related
- 2001-07-23 IL IL15340601A patent/IL153406A0/xx active IP Right Grant
- 2001-07-23 AU AU2001277430A patent/AU2001277430B2/en not_active Expired
- 2001-07-23 WO PCT/CA2001/001069 patent/WO2002008186A2/en not_active Ceased
- 2001-07-23 AT AT01955162T patent/ATE284388T1/de active
- 2001-07-23 HU HU0301745A patent/HUP0301745A3/hu unknown
- 2001-07-23 HR HR20021039A patent/HRP20021039B1/xx not_active IP Right Cessation
- 2001-07-23 DK DK01955162T patent/DK1305286T3/da active
- 2001-07-23 KR KR1020037001117A patent/KR100746814B1/ko not_active Expired - Lifetime
- 2001-07-23 BR BR0112756-0A patent/BR0112756A/pt active Search and Examination
- 2001-07-23 DE DE60107687T patent/DE60107687T2/de not_active Expired - Lifetime
- 2001-07-23 AU AU7743001A patent/AU7743001A/xx active Pending
- 2001-07-23 ES ES01955162T patent/ES2231526T3/es not_active Expired - Lifetime
2002
- 2002-12-12 IS IS6655A patent/IS2170B/is unknown
- 2002-12-12 IL IL153406A patent/IL153406A/en not_active IP Right Cessation
2003
- 2003-01-06 BG BG107438A patent/BG66084B1/bg unknown
- 2003-01-13 EC EC2003004428A patent/ECSP034428A/es unknown
- 2003-01-21 ZA ZA200300554A patent/ZA200300554B/en unknown
- 2003-01-24 NO NO20030374A patent/NO325011B1/no not_active IP Right Cessation

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US3535326A (en) *	1967-03-06	1970-10-20	Sumitomo Chemical Co	Certain tetrahydro carboline derivatives
EP0234708A1 (en) *	1986-01-23	1987-09-02	Merck Frosst Canada Inc.	Tetrahydrocarbazole 1-alkanoic acids
EP0468785A2 (en) *	1990-07-26	1992-01-29	Merck Frosst Canada Inc.	(Quinolin-2-ylmethoxy)tetrahydrocarbazoles as inhibitors of the biosynthesis of leukotrienes

Also Published As

Publication number	Publication date
CZ2003236A3 (cs)	2003-05-14
EE05287B1 (et)	2010-04-15
ZA200300554B (en)	2004-04-23
ECSP034428A (es)	2003-03-10
CA2416867A1 (en)	2002-01-31
WO2002008186A2 (en)	2002-01-31
NO20030374L (no)	2003-01-24
EE200300033A (et)	2004-10-15
EP1305286B1 (en)	2004-12-08
IS6655A (is)	2002-12-12
SK287507B6 (sk)	2010-12-07
HK1058934A1 (en)	2004-06-11
DE60107687D1 (de)	2005-01-13
PL207342B1 (pl)	2010-12-31
SK932003A3 (en)	2003-06-03
BR0112756A (pt)	2003-06-24
CN1214007C (zh)	2005-08-10
BG107438A (bg)	2003-09-30
AU7743001A (en)	2002-02-05
PT1305286E (pt)	2005-04-29
BG66084B1 (bg)	2011-03-31
IS2170B (is)	2006-11-15
KR100746814B1 (ko)	2007-08-06
US6410583B1 (en)	2002-06-25
HRP20021039A2 (en)	2004-10-31
HUP0301745A3 (en)	2010-03-29
UA73787C2 (en)	2005-09-15
AU2001277430B2 (en)	2006-05-25
PL363168A1 (pl)	2004-11-15
WO2002008186A3 (en)	2002-03-21
MXPA03000710A (es)	2003-06-04
NZ523106A (en)	2005-01-28
RS50491B (sr)	2010-03-02
HUP0301745A2 (hu)	2003-09-29
DK1305286T3 (da)	2005-03-14
DE60107687T2 (de)	2005-12-01
DZ3402A1 (fr)	2002-01-31
EP1305286A2 (en)	2003-05-02
JP2004504380A (ja)	2004-02-12
GEP20053595B (en)	2005-08-10
CA2416867C (en)	2008-03-25
KR20030024810A (ko)	2003-03-26
YU97902A (sh)	2006-05-25
ATE284388T1 (de)	2004-12-15
EA006765B1 (ru)	2006-04-28
IL153406A (en)	2008-03-20
ES2231526T3 (es)	2005-05-16
CN1443165A (zh)	2003-09-17
EA200300171A1 (ru)	2003-06-26
NO20030374D0 (no)	2003-01-24
IL153406A0 (en)	2003-07-06
JP4119745B2 (ja)	2008-07-16
NO325011B1 (no)	2008-01-14

Publication	Publication Date	Title
HRP20021039B1 (hr)	2011-03-31	Ciklopentanoindoli, pripravci koji sadržavaju takve spojeve i metode liječenja
EE200200190A (et)	2003-06-16	Trifenüülalkeeni derivaadid ja nende kasutamine selektiivsete östrogeeniretseptorite modulaatoritena
DE69501947D1 (de)	1998-05-07	SUBSTITUIERTE AROMATISCHE VERBINDUNGEN ALS c. AMP PHOSPHODIESTERASE-UND TNF-HEMMER
YU68896A (sh)	1999-07-28	Jedinjenja hinolina i nihazolina od koristi u terapiji
CY1106497T1 (el)	2012-01-25	Νεες αρυλοξυ-αλκυλ-διαλκυλαμινες
YU165391A (sh)	1994-01-20	Derivati indola
YU48855B (sh)	2002-06-19	Heterociklična jedinjenja i njihovi derivati koji su modifikatori dejstva 5-hidroksi-triptamina i postupak njihovog dobijanja
HRP20040977B1 (hr)	2008-04-30	Derivati n-[fenil(piperidin-2-il)metil]benzamida,postupak njihovog pripravljanja i primjena istih u terapiji
DK0673375T3 (da)	1999-10-04	Kondenserede benzoforbindelser
PT1140916E (pt)	2003-03-31	Acetais heteroarilo ciclicos
HRP20070498T3 (en)	2007-12-31	Indanyl-piperazine derivatives, process for their preparation and pharmaceutical compositions containing them
EA200000792A3 (ru)	2001-06-25	Новые пиридиновые соединения, способ их получения и содержащие их фармацевтические композиции
HUP9900584A2 (hu)	1999-07-28	Új benzoil-guanidin-származékok, eljárás előállításukra és gyógyszerkészítmények előállításában való felhasználásuk
ES8700856A1 (es)	1986-11-16	Un procedimiento para la preparacion de compuestos de 1, 4-dihidropiridina
AR007108A1 (es)	1999-10-13	Agentes antitumorales y antivirales alquilantes, procedimiento para su preparacion, utilizacion de los mismos para la fabricacion de un medicamento y composicion farmaceutica que contiene a dichos agentes.
DK217281A (da)	1981-11-20	Fremgangsmaade til fremstilling af 4-hydroxy-3-quinolincarboxylsyrederivater
HRP20000878B1 (hr)	2009-09-30	Kemijska sinteza derivata morfolina
CO4920251A1 (es)	2000-05-29	Compuestos hexahidro 1 h. -pirrolizina 7 a. -heterociclico- substituidos utiles en el control de la transmision sinaptica quimica
MEP12108A (en)	2010-06-10	Novel branched substituted amino derivatives of 3-amino-1-phenyl-1h[1,2,4]triazol, methods for producing them and pharmaceutical compositions containing them
EA200200611A1 (ru)	2002-12-26	Новые тетрагидропиридины, способ их получения и содержащие их фармацевтические композиции
YU47605B (sh)	1995-10-24	Postupak za dobijanje supstituisanih derivata stirena
DK1471059T3 (da)	2007-07-16	2,4,6-tris(dineopentyl-4'-aminobenzalmalonat)-s-triazin, fotobeskyttende kosmetiske sammensætninger indeholdende denne forbindelse og anvendelse af den nævnte forbindelse
YU44592A (sh)	1994-12-28	Derivati 4-aril-3-(heteroarilkarbamido) hinolina
ES8105704A1 (es)	1981-06-01	Procedimiento de preparacion de nuevos eteres oximas, de sussales de adicion acidas y de sus derivados amonicos cuater- narios
YU16196A (sh)	1998-11-05	Upotreba novih benzohinolin-3-ona i njihovih farmaceutski prihvatljivih soli za proizvodnju leka

Legal Events

Date	Code	Title	Description
2004-10-31	A1OB	Publication of a patent application
2005-04-29	ARAI	Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application
2011-03-31	B1PR	Patent granted
2013-07-16	ODRP	Renewal fee for the maintenance of a patent	Payment date: 20130716 Year of fee payment: 13
2015-02-09	PBON	Lapse due to non-payment of renewal fee	Effective date: 20140723